Neuberger Berman Group LLC Lowers Holdings in Genmab A/S (NASDAQ:GMAB)

Neuberger Berman Group LLC lowered its position in shares of Genmab A/S (NASDAQ:GMAB) by 23.5% in the fourth quarter, Holdings Channel reports. The institutional investor owned 33,674 shares of the company’s stock after selling 10,349 shares during the period. Neuberger Berman Group LLC’s holdings in Genmab A/S were worth $703,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in GMAB. Charles Schwab Investment Management Inc. raised its holdings in Genmab A/S by 94.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock worth $636,000 after purchasing an additional 12,654 shares in the last quarter. AIMZ Investment Advisors LLC acquired a new position in Genmab A/S during the 4th quarter worth approximately $3,525,000. HighTower Advisors LLC purchased a new position in shares of Genmab A/S during the 3rd quarter worth approximately $273,000. FMR LLC raised its stake in shares of Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after buying an additional 33,076 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Genmab A/S by 229.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company’s stock valued at $1,033,000 after buying an additional 34,652 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on GMAB shares. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Truist Financial dropped their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. Finally, Sanford C. Bernstein lowered Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday, April 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.17.

Genmab A/S Price Performance

GMAB stock opened at $18.81 on Friday. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $30.41. The firm has a market capitalization of $12.45 billion, a PE ratio of 10.81, a P/E/G ratio of 2.65 and a beta of 1.07. The company’s 50 day simple moving average is $20.48 and its 200-day simple moving average is $21.31.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.